KB-1089

Lifastuzumab

Home » Antibody » Lifastuzumab

Background

NaPi2B is a multi-transmembrane type II sodium-dependent phosphate transporter within the SLC34 solute carrier family. It functions in the transport of inorganic phosphate transcellularly and plays a role in phosphate homeostasis. Normally, it is expressed on the apical surfaces of epithelial cells, including type II pneumocytes in the lung, intestinal epithelium, and epithelial lining of the uterus and fallopian tubes. Lifastuzumab vedotin (LIFA, or DNIB0600A), is an anti-NaPi2B ADC utilizing a humanized IgG1 conjugated to an MMAE payload via a cleavable valine-citrulline linker.

Specifications

Catalog Number:
KB-1089
Cell Line Name:
Lifastuzumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
SLC34A2
Species Reactivity:
Human
Application:
FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS

References

1.?Banerjee S, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinumresistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29(4):917-923. 2.?Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284¨C96.
Please enable JavaScript in your browser to complete this form.